Viyash Scientific targets ₹1,000 cr EBITDA in 2-3 years, pivots to companion animals
Management's May concall reaffirms synergy-led margin expansion and sets an FY27 EBITDA run rate of ~₹800 crore.
What's new
- Management guided for FY27 EBITDA run rate approaching ₹800 crore.
- ₹1,000 crore EBITDA target set for 2-3 years out.
- Strategic pivot toward companion animals and CDMO expansion.
Why it matters
The concall adds confidence that Viyash's post-merger margin trajectory is sustainable beyond the immediate surge. With a clear roadmap to ₹1,000 crore EBITDA, the company is signalling that FY27 is a stepping stone, not a peak.
What we're watching
- Execution on the companion animal strategy.
- CDMO order book build-up.
- Whether the ₹800 crore run rate is achieved in H1FY27 or needs the full year.
The full read
Viyash Scientific's May concall did more than confirm record Q4 numbers — it laid out a strategic roadmap that stretches well beyond the current fiscal. Management pegged the FY27 EBITDA run rate at nearly ₹800 crore, with a ₹1,000 crore target within 2-3 years, built on a deliberate shift toward companion animals and an expanding CDMO franchise. The post-merger synergy outperformance cited suggests margins have room to grow even as the revenue mix evolves. While the numbers were pre-disclosed, the qualitative detail on strategic intent gives a fresher lens to value a mid-cap pharma company shaping its own narrative. The open question is whether operational momentum sustains through the transition — but the call offered enough specificity to make the bull case credible.